Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sight Sciences, Inc.

3.21
+0.13004.22%
Post-market: 3.210.00000.00%16:05 EDT
Volume:385.20K
Turnover:1.21M
Market Cap:165.96M
PE:-3.29
High:3.39
Open:3.28
Low:3.06
Close:3.08
Loading ...

Sight Sciences Announces Preliminary Q4 2024 Revenue Of $18.9M-$19.1M; Surgical Glaucoma Revenue Up 9%; FY24 Revenue $79.7M-$79.9M, Surgical Glaucoma Up 2%

Benzinga
·
14 Jan

Sight Sciences Inc: Q4 Total REV Is Expected to Be in the Range of $18.9 Mln to $19.1 Mln

THOMSON REUTERS
·
14 Jan

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

THOMSON REUTERS
·
14 Jan

Sight Sciences Inc Q4 REV View $20.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
14 Jan

Sight Sciences Reports Positive OMNI Surgical System Data From 36-Month Study

MT Newswires Live
·
08 Jan

Sight Sciences study demonstrates benefits of OMNI system for managing POAG

TIPRANKS
·
08 Jan

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

GlobeNewswire
·
08 Jan

Lake Street Issues a Hold Rating on Sight Sciences (SGHT)

TIPRANKS
·
21 Dec 2024

Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

MT Newswires Live
·
20 Dec 2024

Sight Sciences does BIA of TearCare to treat MGD-associated DED in US

TIPRANKS
·
20 Dec 2024

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

GlobeNewswire
·
20 Dec 2024

Sight Sciences Inc : Citigroup Cuts Target Price to $4.6 From $5.8

THOMSON REUTERS
·
11 Dec 2024

UBS Initiates Sight Sciences at Buy With $5.50 Price Target

MT Newswires Live
·
06 Dec 2024

Sight Sciences Initiated at Buy by UBS

Dow Jones
·
06 Dec 2024

Sight Sciences Inc : UBS Initiates Coverage With Buy Rating and Target Price $5.5

THOMSON REUTERS
·
06 Dec 2024

Sight Sciences initiated with a Buy at UBS

TIPRANKS
·
06 Dec 2024

Promising Growth Prospects for Sight Sciences Driven by TearCare and OMNI Solutions

TIPRANKS
·
06 Dec 2024

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
20 Nov 2024